Skip to main content
. 2022 Sep;17(9):1418–1429. doi: 10.2215/CJN.16751221

Figure 2.

Figure 2.

Obesity blunts the efficacy of adipose MSC-derived EVs as a therapeutic tool in kidney diseases. Lean adipose MSC-derived EVs cover curative effects, whereas obesity or metabolic syndrome changes their cargoes and blunts their ability to alleviate cell or organ injury. HTN, hypertensive nephropathy; MAPK, mitogen-activated protein kinase; miRNA, microRNA; mTOR, mammalian target of rapamycin; RVD, renovascular disease.